Merck has suspended enrollment in clinical trials for the investigational Aurora kinase inhibitor, MK-0457, pending analysis of all efficacy and safety data for the drug. The decision was based on preliminary safety data, in which a clinical safety finding of QTc prolongation was observed in one patient. Merck and collaborative partner Vertex Pharmaceuticals, Inc. have a broad R&D program underway to evaluate Aurora kinase inhibitors targeting cancer. MK-0457 is being studied in a Phas...